SGLT2 inhibitors, along with glucagon-like peptide 1 (GLP-1) receptor agonists, are now recommended as first-line agents for the treatment of T2D to improve cardiovascular outcomes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.